Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Virax Biolabs GroupVRAX -4.08%45 Cash Ratio is 9.40 as of Mar. 2026, which is 50% above its 10-year median of 6.28. GuruFocus rates VRAX with a GF Score™ of 45/100 and a GF Value™ of $3.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,379 Biotechnology companies, Virax Biolabs Group ranks better than 77.81% on this metric.
Virax Biolabs Group has a Cash Ratio of 9.40. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Virax Biolabs Group's Cash Ratio or its related term are showing as below:
VRAX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 6.28 Max: 21.24
Current: 9.4
During the past 7 years, Virax Biolabs Group's highest Cash Ratio was 21.24. The lowest was 0.02. And the median was 6.28.
VRAX's Cash Ratio is ranked better than 77.81% of 1379
companies
in the Biotechnology industry
Industry Median: 2.97
vs VRAX: 9.40
Virax Biolabs Group (NAS:VRAX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Virax Biolabs Group Cash Ratio Related Terms
Virax Biolabs Group Cash Ratio Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Virax Biolabs Group's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (VRAX) has a Cash Ratio of 9.40 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Virax Biolabs Group and its competitors. This is 50% above median its historical median of 6.28. Over the past decade, Virax Biolabs Group's Cash Ratio has ranged from 0.02 to 21.24. According to the industry distribution chart, Virax Biolabs Group ranks #306 out of 1379 companies in the Biotechnology industry, placing it in the top 22.2%.
Is Virax Biolabs Group's Cash Ratio too high?
Virax Biolabs Group's current Cash Ratio of 9.40 is 50% above median its 10-year median of 6.28. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 21.24. The Biotechnology industry median Cash Ratio is 2.97. Virax Biolabs Group's value of 9.40 is 216.5% above this industry median. Based on the distribution chart, Virax Biolabs Group ranks #306 out of 1379 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Cash Ratio compare to ISCO and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #306 out of 1379 companies for Cash Ratio. This places Virax Biolabs Group in the top 22% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.97. Virax Biolabs Group's value of 9.40 is 216.5% above this benchmark. Historically, Virax Biolabs Group's own Cash Ratio has ranged from 0.02 to 21.24 over the past decade. While the company's 10-year median is 6.28 vs. the industry median of 2.97, Virax Biolabs Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.97, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current Cash Ratio of 9.40 is 216.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Virax Biolabs Group and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current Cash Ratio is 9.40, which is 50% above median its own 10-year median of 6.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.56, compared to a current price of $2.82 — trading 20.8% below its estimated fair value. The current Cash Ratio is 9.40, which is 50% above median its 10-year median of 6.28 and 216.5% above the Biotechnology industry median of 2.97. Virax Biolabs Group's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Cash Ratio is 9.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be undervalued.
The current stock price of $2.82 is trading 20.8% below its estimated GF Value™ of $3.56.
GuruFocus considers Virax Biolabs Group to be Modestly Undervalued.
Key valuation signals for VRAX:
Cash Ratio: 9.40 (50% above median its 10-year median of 6.28)
GF Value™: $3.56 vs. price of $2.82 (20.8% below fair value)
Industry Position: 216.5% above the Biotechnology median (#306 of 1379)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
45GF Score
Get the complete analysis for VRAX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
